- Home
- BIVI vs MAIA Comparison
BIVI vs MAIA Comparison
Compare BIVI & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIVI
- MAIA
- Stock Information
- Founded
- BIVI 2013
- MAIA 2018
- Country
- BIVI United States
- MAIA United States
- Employees
- BIVI N/A
- MAIA N/A
- Industry
- BIVI Biotechnology: Pharmaceutical Preparations
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- BIVI Health Care
- MAIA Health Care
- Exchange
- BIVI Nasdaq
- MAIA Nasdaq
- Market Cap
- BIVI 49.8M
- MAIA 52.7M
- IPO Year
- BIVI N/A
- MAIA 2022
- Fundamental
- Price
- BIVI $1.90
- MAIA $2.07
- Analyst Decision
- BIVI Strong Buy
- MAIA
- Analyst Count
- BIVI 1
- MAIA 0
- Target Price
- BIVI $30.00
- MAIA N/A
- AVG Volume (30 Days)
- BIVI 1.5M
- MAIA 251.5K
- Earning Date
- BIVI 02-11-2025
- MAIA 11-12-2024
- Dividend Yield
- BIVI N/A
- MAIA N/A
- EPS Growth
- BIVI N/A
- MAIA N/A
- EPS
- BIVI N/A
- MAIA N/A
- Revenue
- BIVI N/A
- MAIA N/A
- Revenue This Year
- BIVI N/A
- MAIA N/A
- Revenue Next Year
- BIVI N/A
- MAIA N/A
- P/E Ratio
- BIVI N/A
- MAIA N/A
- Revenue Growth
- BIVI N/A
- MAIA N/A
- 52 Week Low
- BIVI $1.04
- MAIA $0.95
- 52 Week High
- BIVI $33.10
- MAIA $5.99
- Technical
- Relative Strength Index (RSI)
- BIVI 30.38
- MAIA 44.66
- Support Level
- BIVI $2.41
- MAIA $1.88
- Resistance Level
- BIVI $2.70
- MAIA $2.63
- Average True Range (ATR)
- BIVI 0.23
- MAIA 0.23
- MACD
- BIVI -0.12
- MAIA 0.02
- Stochastic Oscillator
- BIVI 0.00
- MAIA 30.00
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.